Wealthcare Advisory Partners’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Wealthcare Advisory Partners’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,578	Closed	–	–	710
2022 Q3	$0	Hold	11,578	–	–	﹤0.01%	636
2022 Q2	$4K	Buy	+11,578	New	+$8.1K	﹤0.01%	562

Wealthcare Advisory Partners's CRXT Position: Q4 2022 in Review

Wealthcare Advisory Partners sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q4 2022, closing a stake of 11,578 shares.

Wealthcare Advisory Partners first reported a position in CRXT in Q2 2022 and held it in 2 quarters. The position peaked at $4K in Q2 2022. 0 funds tracked by Wall St. Rank hold CRXT as of Q4 2022.

Wealthcare Advisory Partners reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Wealthcare Advisory Partners sold 11,578 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q4 2022.
Wealthcare Advisory Partners first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Wealthcare Advisory Partners's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $4K in Q2 2022.
0 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Wealthcare Advisory Partners's 13F filing for Q4 2022, filed 13 Feb 2023.